HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $16
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Tango Therapeutics (NASDAQ:TNGX) and raises the price target from $11 to $16.
August 11, 2023 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a 'Buy' rating on Tango Therapeutics and raises the price target from $11 to $16.
The raised price target by HC Wainwright & Co. indicates a positive outlook for Tango Therapeutics. This could potentially lead to an increase in the stock price in the short term as it may attract more investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100